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Karolinska Institutet Stockholm, Stockholm, SwedenAbstractUrinary tract infections are highly common during pregnancy, and can cause serious complications for the mother and baby. Vitamin D,
predominantly obtained from the sunlight, is known to have an effect on the urothelium, with immunomodulatory capacity against
Escherichia coli infection. However, its inﬂuence at this site remains to be further explored. This study therefore investigated its impact
during pregnancy in a population of women who have the possibility of adequate year-round sun exposure. Serum from pregnant
Ugandan women (n = 32) in each trimester of pregnancy, from women after delivery (n = 29) and from never-pregnant controls
(n = 25) was collected. 25-Hydroxyvitamin D (25-OHD), cathelicidin LL-37, human β-defensin 2, interleukin (IL)-8 and soluble CD14
serum concentrations were measured by chemiluminescence immunoassay or ELISA. The ability of serum to inhibit E. coli growth was
tested. The immunomodulatory capacities of these serum samples and 1,25-dihydroxyvitamin D3 were investigated in urothelial cells.
Increases in 25-OHD and LL-37 levels were observed as pregnancy progressed, peaking in the third trimester. Serum 25-OHD levels
were higher in multigravidae than in primigravidae, and correlated positively with maternal age. IL-8 levels were lower in the third
trimester than in the ﬁrst trimester, increased after delivery, but remained below those of never-pregnant women. Similarly, soluble
CD14 concentrations increased after delivery. As gestation advanced, serum had an increased capacity to inhibit E. coli growth. In vitro, it
modulated the IL-8 response to infection in a vitamin D concentration-dependent manner. Our ﬁndings demonstrate that increasing
vitamin D levels as pregnancy advances modulate the innate immune system towards a protective response to infection.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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p://dx.doi.org/10.1016/j.cmi.2014.12.010IntroductionUrinary tract infections are the most commonly experienced
infections in pregnant women [1], with Escherichia coli being the
main causative agent [2]. Such infections may be associated with
serious complications, including pre-term birth, intrauterine
growth restriction, pre-eclampsia, and caesarean delivery [3].
Therefore, treating these patients poses a signiﬁcant challenge
for clinicians [1].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Ramos et al. Vitamin D in pregnancy and UTI 482.e2Vitamin D is essential for human health, and is an important
hormone in pregnancy. It is primarily produced when UVB
radiation from the sun converts 7-dehydrocholesterol in the
skin to vitamin D3; this is followed by metabolic conversion to
25-hydroxyvitamin D (25-OHD) and then to the active form,
1,25-dihydroxyvitamin D3 (1,25D3). It is also, to a lesser extent,
absorbed from dietary sources such as fatty ﬁsh, dairy products,
and fortiﬁed foods [4]. Vitamin D status is best reﬂected by
serum 25-OHD (S-25-OHD) concentrations. Levels of
<50 nmol/L are considered to be deﬁcient, and those of
75 nmol/L are considered to be sufﬁcient [5]. However, the
minimal required and optimal 25-OHD levels are still under
debate, and the ideal levels during pregnancy have not yet been
determined. Factors that reduce uptake of light from the sun,
including dark, pigmented or covered skin and lack of vitamin
D-containing dietary sources, may predispose to deﬁciency
[4,6,7]. Low vitamin D levels during pregnancy may have long-
term repercussions for the child [8].
Vitamin D plays a role in both adaptive and innate immunity.
Its immunomodulatory capacity includes induction of antimi-
crobial peptides (AMPs) [9,10]. Notably, the promoter regions
of the cathelicidin and human β-defensin (hBD) 2 genes contain
consensus vitamin D response elements, allowing vitamin D to
regulate their expression [11]. We have previously shown that,
during E. coli infection, vitamin D regulates cathelicidin
expression in the urinary tract [9]. Its effects in the human body
are potentially far-ranging, as the vitamin D receptor is present
on most immune cells [12], and the ability to modulate the
expression of other immune molecules has been demonstrated
[13].
Here, we sought to investigate the impact of vitamin D
during pregnancy by exploring the vitamin D status of pregnant
Ugandan women, and the serum concentrations of associated
AMPs and other innate immunity markers. We also investigated
the potential of serum to modulate the innate immune
response in an in vitro model of urinary tract infection. Our
ﬁndings overall indicate that vitamin D plays an important role
in innate immune system preparation and protection during
pregnancy.Materials and methodsStudy participants
Pregnant womenwho attendedMulago Hospital Antenatal Clinic
in Kampala, Uganda were recruited to this study. For 32 par-
ticipants, serum samples were collected in the ﬁrst, second and
third trimesters. Sampling time-points were up to 13 weeks of
gestational age, between 22 and 24 weeks, and between 32 and
34 weeks, respectively. In one group of women (n = 29), serumClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inwas collected both in the third trimester and 8–12 months after
delivery. Exclusion criteria included the presence of multiple
gestation, diabetes mellitus, any infection, including human im-
munodeﬁciency virus, or antibiotic use at the time of sampling.
Only samples from women who were not newly pregnant and
who still satisﬁed the original inclusion criteria were included for
after-delivery samples. Samples from never-pregnant, age-
matched women (n = 25) were collected as controls. Written
informed consent was obtained from all participants. The study
was approved by the Regional Ethics Committee in Stockholm,
Sweden and Makerere University Faculty of Medicine Research
and Ethics Committee, Mulago, Uganda.
Analysis of samples
Serum samples were protected from direct light exposure and
were stored frozen at –80°C. All analyses were performed in
Stockholm, Sweden. Serum 25-OHD levels were measured by
chemiluminescence immunoassay with the Liaison 25 OH
Vitamin D Total Assay (DiaSorin, Saluggia, Italy). Concentra-
tions of cathelicidin LL-37 (Hycult Biotech, Uden, The
Netherlands), hBD2, interleukin (IL)-8 and soluble CD14
(sCD14) (R&D Systems Inc, Minneapolis, MN, USA) in serum
and cell culture supernatants were measured by ELISA.
Bacterial culture
The uropathogenic E. coli (UPEC) strain CFT073 was cultured
on blood agar at 37°C. Colonies were suspended in phosphate-
buffered saline, and then centrifuged at 300 g for 10 min to
remove bacterial aggregates. Concentrations were adjusted
spectrophotometrically.
Serum antimicrobial activity
Serum antimicrobial activity was evaluated with sensitivity as-
says as previously described [14,15]. Brieﬂy, UPEC CFT073 was
cultured to mid-logarithmic phase in Luria–Bertani broth, and
then embedded at a ﬁnal concentration of 4.5 × 105 CFU/mL
into molten Luria–Bertani broth with 1% agar and low con-
centrations of electrolytes. After solidiﬁcation in sterile Petri
dishes, 3-mm-diameter holes were made, and 3 μL of serum
was delivered. Following overnight incubation at 37°C, the
diameter of the zone of inhibition was measured.
Cell culture and infection assays
The T24 human bladder epithelial cell line (ATCC HTB-4) and
TERT-NHUC urothelial cells (provided by M. A. Knowles,
Leeds, UK) were maintained in McCoy’s 5A medium with L-
glutamine and 10% fetal bovine serum or EpiLife medium with
60 μM calcium and human keratinocyte growth supplement (Life
Technologies, Carlsbad, CA, USA), respectively. Cultures were
maintained at 37°C in a humidiﬁed incubator with 5% CO2.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e1–482.e7
482.e3 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIT24 cells were grown in 24-well cell culture plates (Costar)
for 24 h. Then, the medium was exchanged with fresh McCoy’s
5A medium supplemented with 10% serum from Ugandan
women in the third trimester of pregnancy who had low
(<50 nmol/L) or high (>80 nmol/L) S-25-OHD levels. After
24 h, cells were infected with UPEC CFT073 (1 × 106 CFU/mL)
and treated with gentamicin (40 μg/mL) for 24 h.
TERT-NHUC cells grown overnight in Primaria 24-well
plates (BD, Franklin Lakes, NJ, USA), and then treated for
24 h with 1,25D3 and gentamicin (40 μg/mL). An ethanol vector
control was maintained alongside. Cells were then infected with
UPEC CFT073 (1 × 106 CFU/mL) for 4 h. For all assays, me-
dium was collected and centrifuged at 300 g for 10 min, and the
supernatants were stored at –80°C pending ELISA testing.
Total RNA extraction and real-time RT-PCR
Total RNA was extracted from cells with the RNeasy Mini kit
(Qiagen, Hilden Germany); 1 μg was transcribed to cDNA with
the High Capacity cDNA Reverse Transcription Kit (Life
Technologies, Carlsbad, CA, USA), according to the manufac-
turers’ instructions. Gene expression was analysed with the
TaqMan Gene Expression Assay for IL-8 (IL8, Hs00174103_m1).
Glyceraldehyde-3-phosphate dehydrogenase was used as an
internal control to calculate relative gene expression.
Statistical analysis
Serum concentrations are presented as mean ± standard de-
viation or median and range. Data were analysed with para-
metric or non-parametric repeated measures ANOVAs or paired
or unpaired t-tests, as appropriate. For in vitro assays, unpaired
t-tests or one-way ANOVAs with Bonferroni’s post hoc test were
used. Pearson’s r-test was used for correlation between S-25-
OHD levels in serum and maternal age. Statistical analyses
were performed with GraphPad Prism Version 5.04. A p-value
of <0.05 was considered to be signiﬁcant.ResultsParticipant characteristics
Pregnant women were aged 18–31 years, with a median 23
years. Never-pregnant controls were aged 20–25 years, with a
median of 23 years. No women were supplemented with
vitamin D. Only one participant reported consuming fortiﬁed
food products before the collection of serum.
S-25-OHD and cathelicidin LL-37 levels increase as
gestation advances and decrease after delivery
Over the course of pregnancy, S-25-OHD deﬁciency
(50 nmol/L) was similarly prevalent at 25%, 22% and 25% in
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthe ﬁrst, second and third trimesters, respectively. After de-
livery, 31% of participants (n = 29) had deﬁcient levels, as
compared with 36% of never-pregnant women (n = 25).
However, S-25-OHD levels increased signiﬁcantly (p < 0.01)
over the course of pregnancy, with higher levels being seen in
the second and third trimesters (Fig. 1(a)). Individual S-25-OHD
levels tended to decrease between the third trimester and after
delivery (68.6 ± 25 nmol/L vs. 62.7 ± 20.7 nmol/L, respectively),
although the difference was not statistically signiﬁcant (p = 0.08).
S-25-OHD levels were signiﬁcantly (p  0.01) lower in
primigravidae (n = 8) than in multigravidae (n = 24) (Fig. 1(b)).
Primigravidae tended to be younger (22 ± 1.7 years vs.
24.5 ± 3.4 years). Overall, there was a positive correlation
between S-25-OHD levels and age (r 0.36, p < 0.05) in each
trimester of pregnancy.
Similarly to S-25-OHD levels, serum LL-37 levels increased
as pregnancy progressed (Fig. 1(c)). They were signiﬁcantly
higher in the third trimester (n = 16, 77 ± 17.7 pg/mL) than
after delivery in the same women (60.8 ± 17.1 pg/mL, p 0.012).
This indicates that LL-37 might be of importance leading up to
and during delivery. Serum hBD2 levels were similar in the ﬁrst
trimester (n = 18, 185.5 ± 178.2 pg/mL), in the third trimester
(n = 18, 196.8 ± 149.3 pg/mL), after delivery (n = 10,
174.9 ± 106.7 pg/mL), and in never-pregnant controls (n = 8,
164.5 ± 67.6 pg/mL).
Serum antimicrobial capacity increases as pregnancy
progresses
Increasing antimicrobial capacity over the course of pregnancy
was observed, in line with changes seen in serum LL-37 levels
(Fig. 1(d)). Interestingly, however, samples from never-pregnant
women inhibited E. coli growth signiﬁcantly (p < 0.01) more
than ﬁrst-trimester, second-trimester and after-delivery sam-
ples (Fig. 1(d)).
Serum IL-8 (S-IL-8)and sCD14 levels are lower during
pregnancy than after delivery
High S-IL-8 levels have been identiﬁed as a marker of preterm
labour [16]. We observed signiﬁcantly lower S-IL-8 levels in the
third trimester than in the ﬁrst trimester, after delivery, and in
never-pregnant controls (p < 0.05; Fig. 2(a)). Levels after de-
livery remained low in comparison with never-pregnant con-
trols, but were higher than in the third trimester. This indicates
that, at certain periods during pregnancy and after delivery,
suppression of IL-8 is important.
We then investigated CD14, a key co-receptor in the host
defence against pathogens [17]. Analysis of samples collected
from women (n = 18) in the ﬁrst and third trimesters revealed
no signiﬁcant difference (1.3 × 106 ± 2.3 × 105 pg/mL vs.
1.3 × 106 ± 2.5 × 105 pg/mL, respectively). Interestingly,ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e1–482.e7
FIG. 1. Serum from Ugandan pregnant women has increasing serum 25-Hydroxyvitamin D (S-25-OHD) and serum LL-37 (S-LL-37) levels and higher
uropathogenic Escherichia coli killing capacity as pregnancy progresses. (a) A signiﬁcant increase in S-25-OHD level was found over time in pregnant
women (n = 32) (p = 0.0004), with never-pregnant controls (n = 25) having lower levels than women in later stages of pregnancy. (b) Higher S-25-
OHD levels were observed in multigravidae than in primigravidae. (c) Circulating cathelicidin LL-37 levels changed signiﬁcantly over the course of
pregnancy (p < 0.0001), and were higher in the third trimester than in never-pregnant women. (d) Serum from pregnant women (n = 9) during
pregnancy and after delivery and from non-pregnant women (n = 20) was tested for the capacity to inhibit growth in an agar sensitivity assay. Repeated
measures one-way ANOVA with Bonferroni’s multiple-comparison test (a, c) or Friedman’s test with Dunn’s multiple-comparison tests (d) was used to
test for differences over the course of pregnancy. Unpaired t-tests were used to compare pregnant and never-pregnant controls (a, c, d), and pri-
migravidae and multigravidae (b).
CMI Ramos et al. Vitamin D in pregnancy and UTI 482.e4however, in women from whom an after-delivery sample was
collected (n = 10), third-trimester sCD14 levels were signiﬁ-
cantly lower than after delivery (1.3 × 106 ± 2.7 × 105 pg/mL vs.
1.6 × 106 ± 3.8 × 105 pg/mL, respectively, p < 0.05).
The urothelial IL-8 response to UPEC is reduced by
vitamin D
We next explored the potential of serum from pregnant
women with different 25-OHD levels to modulate the IL-8
response to UPEC. The urothelial IL-8 response to infectionClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inwas signiﬁcantly less in cells treated with serum containing high
25-OHD levels (>80 nmol/L) than in those treated with low S-
25-OHD levels (<50 nmol/L, p < 0.05) (Figs. 2(b) and (c)). This
indicates that adequately high vitamin D concentrations in the
serum are protective against infection. We could not exclude
the possibility that other serum components may have inﬂu-
enced these ﬁndings, so we next veriﬁed the vitamin D-speciﬁc
role in this immune response. In vitro results showed that the
degree of IL-8 induction was 1,25D3 dose-dependent (Fig. 2(d)
and (e)). At a concentration of 10−8 M, 1,25D3 signiﬁcantlyfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e1–482.e7
FIG. 2. Serum interleukin (IL)-8 levels are reduced during pregnancy and after delivery in Ugandan women, and induction during in vitro infection is
vitamin D concentration-dependent. (A) Serum IL-8 levels in pregnant women (n = 13) were low in the third trimester and after delivery, whereas
ﬁrst-trimester levels were more similar to those of never-pregnant controls (n = 25). Friedman’s test with Dunn’s multiple-comparison test was used
to evaluate IL-8 changes in pregnant women, and the Mann–Whitney test was used to compare each pregnancy time-point with never-pregnant
women. (b, c) Serum-treated T24 urothelial cells infected with uropathogenic Escherichia coli (UPEC) strain CFT073 showed lower IL-8 mRNA
and protein expression levels in the presence of higher serum 25-hydroxyvitamin D (S-25-OHD) levels (>80 nmol/L, n = 8) than those treated with
serum containing lower levels (<50 nmol/L, n = 9). Data from infected cells were ﬁrst normalized to non-infected cells treated with the same woman’s
serum, and then to infected fetal bovine serum-treated cells, which were run as controls alongside. An unpaired t-test was used for statistical analysis.
(d, e) IL-8 mRNA and protein expression in TERT-NHUC urothelial cells treated with or without 1,25-dihydroxyvitamin D3 (1,25D3) (10
−8 M and
10−10 M) for 24 h, and then with or without UPEC CFT073 for 4 h. The data shown are from two or three independent experiments. One-way ANOVAs
with Bonferroni’s post hoc test were used to test for differences between non-infected and infected cells treated with or without 1,25D3.
482.e5 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIreduced IL-8 induction in both non-infected and UPEC-infected
cells in comparison with non-treated cells (p < 0.05; Fig. 2(e)); a
less pronounced effect was seen with a lower vitamin D
concentration.
No vitamin D concentration-dependent differences in CD14
mRNA or sCD14 protein expression were observed in serum-
treated T24 cells (data not shown), and hBD2 and LL-37 mRNA
expression was not detected.DiscussionWe here demonstrate that, in pregnancy, S-25-OHD and
serum LL-37 levels increase, S-IL-8 levels decrease and theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectserum from pregnant women has a higher capacity to inhibit
UPEC growth as gestation advances. After delivery, S-25-OHD
and serum LL-37 levels decrease as S-IL-8 and serum sCD14
levels increase. We show the immunomodulatory capacity of
serum and vitamin D through downregulation of urothelial IL-8
expression during infection.
Uganda is located on the equator between latitudes 4°N and
2°S, and experiences tropical and mostly sunny weather; under
these conditions, it is expected that there will be adequate
exposure to UV light for optimal synthesis of vitamin D,
including in people with dark skin of Fitzpatrick type VI [18].
The combination of dark, pigmented skin and lack of vitamin D-
containing foods in the diet probably contributed to the low S-
25-OHD levels seen in study participants. Fortiﬁed foods areious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e1–482.e7
CMI Ramos et al. Vitamin D in pregnancy and UTI 482.e6rare in Uganda, and only few study participants reported
consuming foods containing naturally occurring vitamin D.
Although some authors have reported similar vitamin D ﬁnd-
ings to ours [19,20], decreasing levels over the course of
pregnancy have also been described [21]. These contradictory
ﬁndings may be attributable to diet, cultural practices related to
pregnancy and sun exposure, genetic differences, or differences
in the method used to measure S-25-OHD. The role of vitamin
D-binding protein (DBP) may also be considered, as vitamin D
circulates mostly bound to DBP. Differences in DBP levels and
afﬁnity in different communities with polymorphisms in the
DBP gene have been associated with low DBP levels [22].
To the best of our knowledge, this is the ﬁrst time that LL-37
and hBD2 serum levels have been proﬁled during pregnancy.
Our ﬁnding of increased LL-37 levels as gestation advances
probably reﬂects progressive immune system strengthening
leading up to delivery. In view of the important role of LL-37 in
the urinary tract [15], the respiratory tract [10], and elsewhere
[23], elevated LL-37 levels probably confer increased immune
protection against such infections. Higher levels at later stages
of pregnancy would also beneﬁt the neonate, as cord plasma
LL-37 levels at delivery have been correlated with maternal
plasma levels [24]. Our ﬁnding of progressively more effective
inhibition of E. coli growth further supports our hypothesis. In
the absence of a statistically signiﬁcant relationship with serum
LL-37, however, we believe that our ﬁndings mirror a syner-
gistic effect of several AMPs in serum [25].
Serum from pregnant women has low IL-8 levels, and we
additionally show that it has the immune potential to down-
regulate the proinﬂammatory IL-8 response to UPEC infection.
Our data indicate the role of vitamin D in modulating this
response, supporting previous ﬁndings that vitamin D has anti-
inﬂammatory functions [26]. In the context of pregnancy, such
an anti-inﬂammatory effect would be beneﬁcial, as a successful
pregnancy requires ﬁne-balanced immunomodulation, while
proinﬂammatory processes are associated with labour [27].
In line with changes in S-IL-8 levels, we here demonstrate
higher serum sCD14 levels after delivery. Whereas we were
able to detect CD14 mRNA expression in T24 cells, contra-
dictory ﬁndings have previously been reported in these cells
[17,28]; differences in cell culture practice may underlie this
[28]. Furthermore, we did not ﬁnd a serum vitamin D
concentration-dependent effect on its expression during
infection. We thus support the idea that already circulating
sCD14 is important for recognition of bacterial lipopolysac-
charide in the urothelium [17].
We found vitamin D deﬁciency to be common among both
pregnant and non-pregnant Ugandan women, despite the year-
round possibility of sun exposure. Interestingly, however, older
pregnant women had higher levels than younger women, a ﬁndingClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inin line with those of others [29]. Recent recommendations sug-
gest that intake of up to 2000 IU/day of cholecalciferol may be
required to achieve sufﬁcient S-25-OHD levels during pregnancy
[30]. The impact of maternal vitamin D deﬁciency cannot be
underestimated, as the fetus depends on 25-OHD crossing
through the placenta, and breastmilk is an important sourceof 25-
OHD after birth [31]. The increased risk of hypocalcaemia and
rickets in the baby [32] indicate that supplementation would be
valuable for this or any other patient group at risk of deﬁciency.
Our results demonstrate that, even in locations where there
is adequate access to sunlight, there is a risk of vitamin D
deﬁciency during pregnancy. In view of our ﬁndings, we suggest
that there may be a need for supplementation of pregnant
women who have deﬁcient S-25-OHD levels. This would have
the potential to alter the immune responses against infection
away from potentially detrimental inﬂammatory processes and
more towards protective antimicrobial activity.Transparency declarationThe authors declare that they have no conﬂicts of interest.AcknowledgementsWe thank all volunteers who provided samples that contrib-
uted to this work. We also thank Anthony Nantume, Regina
Nakubulwa and Lisbeth Norman for excellent technical assis-
tance. This work was supported by grants from the Swedish
Research Council (56X-20356), ALF Project Funding, grants
from the Swedish International Development Cooperation
Agency, and the Karolinska Institutet.References[1] Foxman B. Epidemiology of urinary tract infections: incidence,
morbidity, and economic costs. Am J Med 2002;113(Suppl. 1A):
5S–13S.
[2] Delzell JE, Lefevre ML. Urinary tract infections during pregnancy. Am
Fam Physician 2000;61(3):713–21.
[3] Mazor-Dray E, Levy A, Schlaeffer F, Sheiner E. Maternal urinary tract
infection: is it independently associated with adverse pregnancy
outcome? J Maternal-Fetal Neonatal Med 2009;22(2):124–8.
[4] Lips P, van Schoor NM, de Jongh RT. Diet, sun, and lifestyle as de-
terminants of vitamin D status. Ann N Y Acad Sci 2014;1317(1):92–8.
[5] Holick MF. Vitamin D status: measurement, interpretation, and clinical
application. Ann Epidemiol 2009;19(2):73–8.
[6] Holick MF. Vitamin D deﬁciency. N Engl J Med 2007;357(3):266–81.
[7] Sääf M, Fernell E, Kristiansson F. Barnevik Olsson M, Gustafsson SA,
Bågenholm G. Severe vitamin D deﬁciency in pregnant women of
Somali origin living in Sweden. Acta Paediatr 2011;100(4):612–4.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e1–482.e7
482.e7 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMI[8] Javaid MK, Crozier SR, Harvey NC, Gale CR, Dennison EM,
Boucher BJ, et al. Maternal vitamin D status during pregnancy and
childhood bone mass at age 9 years: a longitudinal study. Lancet
2006;367(9504):36–43.
[9] Hertting O, Holm A, Luthje P, Brauner H, Dyrdak R, Jonasson AF,
et al. Vitamin D induction of the human antimicrobial peptide cath-
elicidin in the urinary bladder. PloS One 2010;5(12):e15580.
[10] Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-
mediated human antimicrobial activity against Mycobacterium tuber-
culosis is dependent on the induction of cathelicidin. J Immunol
2007;179(4):2060–3.
[11] Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al.
Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of anti-
microbial peptide gene expression. J Immunol 2004;173(5):2909–12.
[12] Chun RF, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin
D on immune function: lessons learned from genome-wide analysis.
Front Physiol 2014;5:1–15. Article ID: 151.
[13] Khoo AL, Chai LY, Koenen HJ, Oosting M, Steinmeyer A, Zuegel U,
et al. Vitamin D(3) down-regulates proinﬂammatory cytokine response
to Mycobacterium tuberculosis through pattern recognition receptors
while inducing protective cathelicidin production. Cytokine
2011;55(2):294–300.
[14] Fazliana M, Ramos NL, Luthje P, Sekikubo M, Holm A, Wan
Nazaimoon WM, et al. Labisia pumila var. alata reduces bacterial load
by inducing uroepithelial cell apoptosis. J Ethnopharmacol 2011;136(1):
111–6.
[15] Chromek M, Slamova Z, Bergman P, Kovacs L, Podracka L, Ehren I,
et al. The antimicrobial peptide cathelicidin protects the urinary tract
against invasive bacterial infection. Nat Med 2006;12(6):636–41.
[16] von Minckwitz G, Grischke EM, Schwab S, Hettinger S, Loibl S,
Aulmann M, et al. Predictive value of serum interleukin-6 and -8 levels
in preterm labor or rupture of the membranes. Acta Obstet Gynecol
Scand 2000;79(8):667–72.
[17] Bäckhed F, Meijer L, Normark S, Richter-Dahlfors A. TLR4-dependent
recognition of lipopolysaccharide by epithelial cells requires sCD14.
Cell Microbiol 2002;4(8):493–501.
[18] Webb AR, Engelsen O. Calculated ultraviolet exposure levels for a
healthy vitamin D status. Photochem Photobiol 2006;82(6):1697–703.
[19] Charatcharoenwitthaya N, Nanthakomon T, Somprasit C,
Chanthasenanont A, Chailurkit LO, Pattaraarchachai J, et al. Maternal
vitamin D status, its associated factors and the course of pregnancy in
Thai women. Clin Endocrinol 2013;78(1):126–33.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect[20] Vandevijvere S, Amsalkhir S, Van Oyen H, Moreno-Reyes R. High
prevalence of vitamin D deﬁciency in pregnant women: a national
cross-sectional survey. PloS One 2012;7(8):e43868.
[21] Narchi H, Kochiyil J, Zayed R, Abdulrazzak W, Agarwal M. Maternal
vitamin D status throughout and after pregnancy. J Obstet Gynaecol
2010;30(2):137–42.
[22] Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M,
et al. Vitamin D-binding protein and vitamin D status of black Amer-
icans and white Americans. N Engl J Med 2013;369(21):1991–2000.
[23] van der Does AM, Bergman P, Agerberth B, Lindbom L. Induction of
the human cathelicidin LL-37 as a novel treatment against bacterial
infections. J Leukocyte Biol 2012;92(4):735–42.
[24] Mandic Havelka A, Yektaei-Karin E, Hultenby K, Sorensen OE,
Lundahl J, Berggren V, et al. Maternal plasma level of antimicrobial
peptide LL37 is a major determinant factor of neonatal plasma LL37
level. Acta Paediatr 2010;99(6):836–41.
[25] Chen X, Niyonsaba F, Ushio H, Okuda D, Nagaoka I, Ikeda S, et al.
Synergistic effect of antibacterial agents human beta-defensins, cath-
elicidin LL-37 and lysozyme against Staphylococcus aureus and Escher-
ichia coli. J Dermatol Sci 2005;40(2):123–32.
[26] Gunville CF, Mourani PM, Ginde AA. The role of vitamin D in pre-
vention and treatment of infection. Inﬂamm Allergy Drug Targets
2013;12(4):239–45.
[27] Schminkey DL, Groer M. Imitating a stress response: a new hypothesis
about the innate immune system’s role in pregnancy. Med Hypotheses
2014;82(6):721–9.
[28] Schilling JD, Martin SM, Hunstad DA, Patel KP, Mulvey MA, Justice SS,
et al. CD14- and Toll-like receptor-dependent activation of bladder
epithelial cells by lipopolysaccharide and type 1 piliated Escherichia coli.
Infect Immun 2003;71(3):1470–80.
[29] Savvidou MD, Makgoba M, Castro PT, Akolekar R, Nicolaides KH.
First-trimester maternal serum vitamin D and mode of delivery. Br J
Nutr 2012;108(11):1972–5.
[30] Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA,
Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D
deﬁciency: an Endocrine Society clinical practice guideline. J Clin
Endocrinol Metab 2011;96(7):1911–30.
[31] Thandrayen K, Pettifor JM. Maternal vitamin D status: implications for
the development of infantile nutritional rickets. Rheumatic Dis Clin
North Am 2012;38(1):61–79.
[32] Kovacs CS. Maternal vitamin D deﬁciency: fetal and neonatal implica-
tions. Semin Fetal Neonatal Med 2013;18:129–35.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e1–482.e7
